Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionCombination of oral SAR245409 (XL765) and oral MSC1936369B
Molecular Target Phosphoinositide 3-kinase (PI3K) ; Mammalian target of rapamycin (mTOR) (FRAP) (RAFT1)
Mechanism of ActionMammalian target of rapamycin (mTOR) kinase inhibitor; Phosphoinositide 3-kinase (PI3K) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationOvarian cancer
Indication DetailsTreat ovarian cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today